Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Apr 18, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Drug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Fineline Cube Apr 18, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts

Fineline Cube Apr 18, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...

Company Deals

PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion

Fineline Cube Apr 18, 2023

China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...

Company Deals

Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development

Fineline Cube Apr 18, 2023

Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic...

Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Company Drug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

Fineline Cube Apr 17, 2023

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...

Company Deals

Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech

Fineline Cube Apr 17, 2023

Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...

Company Drug

Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)

Fineline Cube Apr 17, 2023

Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...

Company Deals

Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development

Fineline Cube Apr 17, 2023

Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...

Company Deals

Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply

Fineline Cube Apr 17, 2023

Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...

Company Drug

CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine

Fineline Cube Apr 17, 2023

CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...

Company Drug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

Fineline Cube Apr 17, 2023

JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...

Company

Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 17, 2023

Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...

Company

Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang

Fineline Cube Apr 17, 2023

China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...

Policy / Regulatory

Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng

Fineline Cube Apr 17, 2023

The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...

Company Drug

Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial

Fineline Cube Apr 17, 2023

China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...

Company Drug

AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery

Fineline Cube Apr 17, 2023

China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...

Medical Device Policy / Regulatory

NHC Proposes Updates to Access Standards for Class A and B Medical Equipment

Fineline Cube Apr 17, 2023

The National Healthcare Commission (NHC) has released two proposed updates to the Access Standards for...

Posts pagination

1 … 566 567 568 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.